Cardiology - Original Articles Open access

Hypertension cost in primary health care facilities in Morocco: a cost-of-illness study

Authors

Published
29 July 2026
Issue
Early Access
Section
Cardiology - Original Articles
DOI
10.4081/monaldi.2026.3816

Abstract

Hypertension in low- and middle-income countries such as Morocco has an economic importance due to its high prevalence and cost. The aim of this study is to estimate direct health costs (DHC) for hypertension patients followed in primary health care facilities in Morocco. A cost of illness prevalence-based study was carried out on hypertension patients followed in public primary health care facilities in Fez. Data were collected using a questionnaire, including sociodemographic and clinical data and healthcare resources utilization: medical tests, medications, and medical visits. DHC was estimated using a bottom-up approach method from a societal perspective and a one-year time horizon. Official prices published by the national agency for health insurance were adopted as unit costs. Cost was compared to annual household income for calculating the catastrophic cost.  Cost is defined as catastrophic if it exceeds 10% of annual household income. We included 146 patients. The mean age was 60.7±11.1 years; 70.5% were men. More than half (54.2%) of participants had uncontrolled hypertension. The direct medical cost was estimated at 368.8±120.8 United States dollars per patient. Costs of medical tests and drugs represented, respectively, 58.6% and 30.5% of total direct cost. The incidence of catastrophic cost was 76.8%. Hypertensive patients incur substantial direct costs. High rates of catastrophic costs illustrate the urgency of improving financial risk protection for these patients and strengthening primary care to ensure the affordability of hypertension care.  

Keywords

Ethics Approval

Ethical approval for the study was obtained from the Fez University Hospital Ethics Committee (Ref: 21/2017).

References

  1. WHO. Hypertension. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension.
  2. WHO. Uncontrolled high blood pressure puts over a billion people at risk. Available from: https://www.who.int/news/item/23-09-2025-uncontrolled-high-blood-pressure-puts-over-a-billion-people-at-risk
  3. Wierzejska E, Giernaś B, Lipiak A, et al. A global perspective on the costs of hypertension: a systematic review. Arch Med Sci 2020;16:1078‑91. DOI: https://doi.org/10.5114/aoms.2020.92689
  4. Gheorghe A, Griffiths U, Murphy A, et al. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health 2018;18:975. DOI: https://doi.org/10.1186/s12889-018-5806-x
  5. WHO. Morocco hypertension profile. Available from: https://cdn.who.int/media/docs/default-source/country-profiles/hypertension/hypertension-2023/hypertension_mar_2023.pdf?sfvrsn=b820c359_4&download=true
  6. WHO. 2017-2018 STEPS country report Morocco. Available from: https://www.who.int/publications/m/item/2017-2018-steps-country-report-morocco
  7. El Achhab Y, Nazek L, Maalej M, et al. Prevalence, control and risk factors related to hypertension among Moroccan adults: a multicentre study. East Mediterr Health J 2019;25:447‑56. DOI: https://doi.org/10.26719/emhj.18.057
  8. WHO. Health profile 2015. Morocco. Available from: https://apps.who.int/iris/bitstream/handle/10665/253774/EMROPUB_2016_EN_19275.pdf?sequence=1&isAllowed=y
  9. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006;77:51‑63. DOI: https://doi.org/10.1016/j.healthpol.2005.07.016
  10. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol 2014;20:327‑37. DOI: https://doi.org/10.3350/cmh.2014.20.4.327
  11. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension 2017;71:6. DOI: https://doi.org/10.1161/HYP.0000000000000075
  12. WHO. Obésité et surpoids. Available from: https://www.who.int/fr/news-room/fact-sheets/detail/obesity-and-overweight.
  13. Byford S, Torgerson DJ, Raftery J. Cost of illness studies. BMJ 2000;320:1335. DOI: https://doi.org/10.1136/bmj.320.7245.1335
  14. Caisse Nationale des Organismes de Prévoyance Sociale (CNOPS). Tarification Nationale de Référence (TNR): Consultations et visites, biologie et radiologie. Available from: https://www.cnops.org.ma/fr/Reglementation_page
  15. Wagstaff A, Flores G, Hsu J, et al. Progress on catastrophic health spending in 133 countries: a retrospective observational study. Lancet Glob Health 2018;6:e169‑79. DOI: https://doi.org/10.1016/S2214-109X(17)30429-1
  16. Oyando R, Njoroge M, Nguhiu P, et al. Patient costs of hypertension care in public health care facilities in Kenya. Int J Health Plann Manage 2019;34:e1166‑78. DOI: https://doi.org/10.1002/hpm.2752
  17. Alefan Q, Ibrahim MIM, Razak TA, Ayub A. Cost of treating hypertension in Malaysia. Asian J Pharm Clin Res 2009;2:1-5.
  18. Le C, Zhankun S, Jun D, Keying Z. The economic burden of hypertension in rural south-west China. Trop Med Int Health 2012;17:1544‑51. DOI: https://doi.org/10.1111/j.1365-3156.2012.03087.x
  19. Berto P, Esposti ED, Ruffo P, Buda S, Esposti LD, Sturani A, et al. The Pandora project: cost of hypertension from a general practitioner database. Blood Pressure 2002;11:151‑6. DOI: https://doi.org/10.1080/080370502760050386
  20. Kankeu HT, Saksena P, Xu K, Evans DB. The financial burden from non-communicable diseases in low- and middle-income countries: a literature review. Health Res Policy Syst 2013;11:31. DOI: https://doi.org/10.1186/1478-4505-11-31
  21. Murphy A, Jakab M, McKee M, Richardson E. Persistent low adherence to hypertension treatment in Kyrgyzstan: how can we understand the role of drug affordability? Health Policy Plan 2016;31:1384‑90. DOI: https://doi.org/10.1093/heapol/czw080
  22. MacMahon S, Alderman MH, Lindholm LH, et al. Blood-pressure-related disease is a global health priority. Am J Hypertens 2008;21:843‑4. DOI: https://doi.org/10.1038/ajh.2008.223
  23. Attaei MW, Khatib R, McKee M, et al. Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet Public Health 2017;2:e411‑9.
  24. Mbui JM, Oluka MN, Guantai EM, et al. Prescription patterns and adequacy of blood pressure control among adult hypertensive patients in Kenya; findings and implications. Expert Rev Clin Pharmacol 2017;10:1263‑71. DOI: https://doi.org/10.1080/17512433.2017.1371590
  25. Mohan V, Seedat YK, Pradeepa R. The rising burden of diabetes and hypertension in southeast asian and african regions: need for effective strategies for prevention and control in primary health care settings. Int J Hypertens 2013;2013:409083. DOI: https://doi.org/10.1155/2013/409083
  26. Goudge J, Gilson L, Russell S, et al. Affordability, availability and acceptability barriers to health care for the chronically ill: longitudinal case studies from South Africa. BMC Health Serv Res 2009;9:75. DOI: https://doi.org/10.1186/1472-6963-9-75
  27. Ukwaja KN, Alobu I, Abimbola S, Hopewell PC. Household catastrophic payments for tuberculosis care in Nigeria: incidence, determinants, and policy implications for universal health coverage. Infect Dis Poverty 2013;2:21. DOI: https://doi.org/10.1186/2049-9957-2-21
  28. World Bank & Haut-Commissariat au Plan (HCP). (2018). Poverty in Morocco: Challenges and Opportunities. Available from: https://www.worldbank.org/en/country/morocco/publication/poverty-in-morocco-challenges-and-opportunities
  29. Wong MCS, Tam WWS, Cheung CSK, et al. Drug adherence and the incidence of coronary heart disease- and stroke-specific mortality among 218,047 patients newly prescribed an antihypertensive medication: a five-year cohort study. Int J Cardiol 2013;168:928‑33. DOI: https://doi.org/10.1016/j.ijcard.2012.10.048
  30. Shin S, Song H, Oh SK, et al. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients. Hypertens Res 2013;36:1000‑5. DOI: https://doi.org/10.1038/hr.2013.85
  31. Llubes-Arrià L, Briones-Vozmediano E, Mateos JT, et al. Gender differences in self-management activation among patients with multiple chronic diseases: a qualitative study. Arch Public Health 2025;83:200. DOI: https://doi.org/10.1186/s13690-025-01686-1
  32. Golinelli D, Sanmarchi F, Guarducci G, et al. Gender differences in healthcare utilization across Europe: Evidence from the European Health Interview Survey. Health Policy 2025;162:105448. DOI: https://doi.org/10.1016/j.healthpol.2025.105448
  33. Bertakis KD, Azari R, Helms LJ, et al. Gender differences in the utilization of health care services. J Fam Pract 2000;49:147‑52.
  34. Bähler C, Huber CA, Brüngger B, Reich O. Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a claims data based observational study. BMC Health Serv Res 2015;15:23. DOI: https://doi.org/10.1186/s12913-015-0698-2
  35. Picco L, Achilla E, Abdin E, et al. Economic burden of multimorbidity among older adults: impact on healthcare and societal costs. BMC Health Serv Res 2016;16:173. DOI: https://doi.org/10.1186/s12913-016-1421-7
  36. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011;10:430‑9. DOI: https://doi.org/10.1016/j.arr.2011.03.003

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.